Abstract:Introduction: Human leukocyte antigen (HLA) plays a major role in the interaction between the immune system and oncogenic process in various types of tumors. Emerging data suggests that the HLA system may have profound effects on response to immunotherapy and other types of therapy. Structural defects in HLA genes and variation in methylation have been reported to play a role in the expression of various HLA-I and HLA-II genes. Furthermore, an association between the expression of specific HLA-I or HLA-II genes and prognosis and outcome has been reported in some types of leukemia. Since HLA-I is expressed on all cells while HLA-II is expressed mainly in antigen presenting cells, we hypothesized that profiling the expression levels of both HLA-I and HLA-II in the bone marrow of patients with various myeloid neoplasms may provide information on the interaction between the microenvironment and the leukemic cell in these diseases. We used next generation sequencing to evaluate the expression level of HLA-I and HLA-II genes in myeloid neoplasms and compared these levels to normal bone marrow control. We used targeted next generation sequencing (NGS) for quantification of the RNA expression of 15 HLA-I and HLA-II genes. Methods: RNA was extracted from fresh bone marrow aspiration samples from 115 acute myeloid leukemia (AML), 196 clonal hematopoiesis of indeterminate potential (CHIP), 84 myeloproliferative neoplasm (MPN), 177 myelodysplastic syndrome (MDS), 40 acute lymphoblastic leukemia (ALL), and 279 normal bone marrow cases. RNA sequencing was performed using a targeted hybrid capture panel. The sequenced HLA-I genes were HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, and HLA-H. The sequenced HLA-II genes were: HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DQB2, HLA-DRA, HLA-DRB1, HLA-DRB5, and HLA-DRB6. Salmon v1.4.0 software was used for expression quantification (TPM). To evaluate the depth of the significance in variation of the expression profiles between diseases we tested machine learning algorithm (random forest) incorporating the expression of all 15 genes in blindly classifying diseases. Two thirds of samples were used for training the random forest algorithm and one third was used for testing. Results: Bone marrow samples with CHIP showed no significant difference from normal bone marrow in level of expression of HLA-I genes but showed significantly (P <0.001) lower level of most HLA-II markers (DMB, DQA1, DQB2, DRB1, and DRB5). The same pattern was observed in MDS samples. In contrast, AML showed significant (P < 0.001) increase in the expression of both HLA-1 genes (A, C, and F) and HLA-II genes (DQA1, DPA1, DQB1, DRB6, and DPB1). Bone marrow samples from ALL patients showed significantly (P< 0.001) higher expression levels in DRB1 and DQA1 as compared with normal bone marrow. MPN samples showed no statistically significant difference from normal BM in any of the HLA-I or HLA-II genes, after adjusting for multiple testing. Machine leaning algorithm poorly classified MDS and AML and suggests complex overlap between the two diseases in HLA response. In contrast, the machine learning algorithm showed significant difference between MPN, MDS, and AML, and ability to distinguish all MPN cases with AUC of 0.738 (95% CI : 0.546-0.930) in the testing set (see figure). Conclusions: These findings show that the bone marrow microenvironment immune profile in MDS and CHIP likely plays a major role in the disease. Furthermore, this data suggests that this immune microenvironment is critical in CHIP and perhaps that therapeutic approaches supporting this immune microenvironment may help in preventing CHIP from progressing to MDS. The data also supports that AML is a disease that completely overwhelms the HLA immune system. In contrast, MPN appears to evade the HLA system and perhaps activating this system may help in the therapy of MPN.

Epigenetic Regulation of Differential Hla-A Allelic Expression Levels

Single Nucleotide Polymorphisms in the Regulatory Regions of the HLA-DRB-expressed Genes

Variation within the non-coding genome influences genetic and epigenetic regulation of the human leukocyte antigen genes

Sequence and Phylogenetic Analysis of the Untranslated Promoter Regions for Hla Class I Genes

Differential Microrna Regulation of HLA-C Expression and Its Association with HIV Control.

MHC Locus Variation

The influence of HLA genetic variation on plasma protein expression

Influence of HLA-C Expression Level on HIV Control

Exploring the genetic basis of human population differences in DNA methylation and their causal impact on immune gene regulation

Influence of HLA-C expression level on HIV control.

HLA-E Allelic Variants: CORRELATING DIFFERENTIAL EXPRESSION, PEPTIDE AFFINITIES, CRYSTAL STRUCTURES, AND THERMAL STABILITIES

Comparison between qPCR and RNA-seq reveals challenges of quantifying HLA expression

Dna Methylation As A Mediator Of Hla-Drb1(Star)15:01 And A Protective Variant In Multiple Sclerosis

DNA methylation as a mediator of HLA-DRB1*15 : 01 and a protective variant in multiple sclerosis

Deregulation of HLA-Class I and Class II Genes in Chip, MDS, and Acute Leukemia and Similarity between Chip and MDS in HLA Profile

Imputing Amino Acid Polymorphisms in Human Leukocyte Antigens

Hla-Drb1 May Be Antagonistically Regulated By The Coordinately Evolved Promoter And 3 '-Utr Under Stabilizing Selection

HLA-E Allelic Variants

Structural and Functional Distinctiveness of HLA-A2 Allelic Variants

Nucleotide alterations in the HLA-C class I gene can cause aberrant splicing and marked changes in RNA levels in a polymorphic context-dependent manner

Genome Wide Differences of Gene Expression Associated with HLA-DRB1 Genotype in Multiple Sclerosis: a Pilot Study.